文献速递妇产影像US

瑞典无症状单胎妊娠宫颈长度筛查与孕酮治疗预防自发性早产的成本效果分析

Cost-effectiveness of cervical length screening and progesterone treatment to prevent spontaneous preterm delivery in Sweden.
PubMed 文献 · Ultrasound Obstet Gynecol · 2022-01-01

基于瑞典CERVIX研究的决策分析模型,评估无症状单胎妊娠预防自发性早产策略的成本效果。所有干预策略健康结局均优于不筛查,低风险筛查策略在孕18+0至20+6周成本效果最佳,ACER为2200美元,在21+0至23+6周则成本较高,ACER为36800美元。作者认为宫颈长度筛查联合孕酮治疗可能在瑞典具有成本效果。

要点

  • 低风险筛查策略在孕18+0至20+6周成本效果最佳,ACER为2200美元,优于其他策略。
  • 低风险筛查策略在孕21+0至23+6周成本较高,ACER为36800美元,相比其他方案成本过高。
  • 成本效果对孕酮疗效和孕期病假导致的生产力损失特别敏感。

核心结论

  • 无症状单胎妊娠中,宫颈长度筛查联合短宫颈孕酮治疗等预防自发性早产的干预措施在瑞典可能具有成本效果。

研究设计与样本

  • 基于瑞典CERVIX研究的决策分析模型,构建决策树与马尔可夫模型,时间跨度100年,采用社会视角,数据来自瑞典医疗保健背景。

诊断标准与关键数值

  • 短宫颈定义为宫颈长度≤25 mm(基础病例),概率源自CERVIX研究。
  • 孕酮效果假设:孕33周前自发性早产减少30%,孕33至36周自发性早产减少10%(基于文献)。
  • 支付意愿上限为500000瑞典克朗(56000美元),依据瑞典国家卫生与福利委员会建议。
  • 低风险筛查策略在孕18+0至20+6周的平均成本效果比(ACER)为2200美元。
  • 低风险筛查策略在孕21+0至23+6周的平均成本效果比(ACER)为36800美元。

局限性

  • 成本效果对孕酮疗效和孕期病假导致的生产力损失特别敏感。
  • 脑瘫成本基于丹麦数据,而非瑞典数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To estimate the cost-effectiveness of strategies to prevent spontaneous preterm delivery (PTD) in asymptomatic singleton pregnancies, using prevalence and healthcare cost data from the Swedish healthcare context.

METHODS: We designed a decision analytic model based on the Swedish CERVIX study to estimate the cost-effectiveness of strategies to prevent spontaneous PTD in asymptomatic women with a singleton pregnancy. The model was constructed as a combined decision-tree model and Markov model with a time horizon of 100 years. Four preventive strategies, namely 'Universal screening', 'High-risk-based screening' (i.e. screening of high-risk women only), 'Low-risk-based screening' (i.e. treatment of high-risk population and screening of remaining women) and 'Nullipara screening' (i.e. treatment of high-risk population and screening of nulliparous women only), included second-trimester cervical length (CL) screening by transvaginal ultrasound followed by vaginal progesterone treatment in the case of a short cervix. A fifth preventive strategy involved vaginal progesterone treatment of women with previous spontaneous PTD or late miscarriage but no CL screening ('No screening, treat high-risk group'). For comparison, we used a sixth strategy implying no specific intervention to prevent spontaneous PTD, reflecting the current situation in Sweden ('No screening'). Probabilities for a short cervix (CL ≤ 25 mm; base-case) and for spontaneous PTD at < 33 + 0 weeks and at 33 + 0 to 36 + 6 weeks were derived from the CERVIX study, and probabilities for stillbirth, neonatal mortality and long-term morbidity (cerebral palsy) from Swedish health data registers. Costs were based on Swedish data, except costs for cerebral palsy, which were based on Danish data. We assumed that vaginal progesterone reduces spontaneous PTD before 33 weeks by 30% and spontaneous PTD at 33-36 weeks by 10% (based on the literature). All analyses were from a societal perspective. We expressed the effectiveness of each strategy as gained quality-adjusted life years (QALYs) and presented cost-effectiveness as average (ACER; average cost per gained QALY compared with 'No screening') and incremental (ICER; difference in costs divided by the difference in QALYs for each of two strategies being compared) cost-effectiveness ratios. We performed deterministic and probabilistic sensitivity analysis. The results of the latter are shown as cost-effectiveness acceptability curves. Willingness-to-pay was set at a maximum of 500 000 Swedish krona (56 000 US dollars (USD)), as suggested by the Swedish National Board of Health and Welfare.

RESULTS: All interventions had better health outcomes than did 'No screening', with fewer screening-year deaths and more lifetime QALYs. The best strategy in terms of improved health outcomes was 'Low-risk-based screening', irrespective of whether screening was performed at 18 + 0 to 20 + 6 weeks (Cx1) or at 21 + 0 to 23 + 6 weeks (Cx2). 'Low-risk-based screening' at Cx1 was cost-effective, while 'Low-risk-based screening' at Cx2 entailed high costs compared with other alternatives. The ACERs were 2200 USD for 'Low-risk-based screening' at Cx1 and 36 800 USD for 'Low-risk-based screening' at Cx2. Cost-effectiveness was particularly sensitive to progesterone effectiveness and to productivity loss due to sick leave during pregnancy. The probability that 'Low-risk-based screening' at Cx1 is cost-effective compared with 'No screening' was 71%.

CONCLUSION: Interventions to prevent spontaneous PTD in asymptomatic women with a singleton pregnancy, including CL screening with progesterone treatment of cases with a short cervix, may be cost-effective in Sweden. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wikström T, Kuusela P, Jacobsson B, et al. Cost-effectiveness of cervical length screening and progesterone treatment to prevent spontaneous preterm delivery in Sweden. Ultrasound Obstet Gynecol. 2022. PMID: 35195310. doi:10.1002/uog.24884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。